Guolian Minsheng Securities·2026-03-31 09:49Investment Rating - The report maintains a "Recommended" rating for the company [5]. Core Insights - The company achieved a revenue of 6.83 billion yuan in 2025, representing a year-on-year growth of 3.5%. The net profit attributable to shareholders reached 0.89 billion yuan, with a significant year-on-year increase of 119.2%. However, the net profit excluding non-recurring items decreased by 58.5% to 0.36 billion yuan [2][3]. - The company is experiencing a recovery in domestic demand and an increase in overseas orders, leading to a positive trend in revenue and profit. The total new orders reached 10.16 billion yuan, up 20.7% year-on-year, and the amount of contracts to be executed was 18.2 billion yuan, an increase of 15.3% [2][3]. - The clinical trial technical services business stabilized, with revenue of 3.27 billion yuan, a 2.8% increase. The SMO business saw growth driven by overseas orders, with ongoing SMO projects increasing from 2,253 to 2,753 [3]. Summary by Relevant Sections Financial Performance - In 2025, the company reported total revenue of 6.83 billion yuan, with a growth rate of 3.5%. The net profit attributable to shareholders was 0.89 billion yuan, reflecting a growth rate of 119.2% [4][10]. - The projected financial performance for 2026 to 2028 includes revenues of 7.62 billion yuan, 8.61 billion yuan, and 9.83 billion yuan, with corresponding net profits of 1.19 billion yuan, 1.58 billion yuan, and 2.04 billion yuan [4][10]. Business Segments - The clinical trial technical services segment generated 3.27 billion yuan in revenue, while the clinical trial-related services and laboratory services segment achieved 3.45 billion yuan, marking a 4.6% increase [3]. - The SMO business benefited from strong demand for cross-border orders, contributing to the overall growth of the company [3]. Future Outlook - The company is expected to continue its recovery, with projections indicating a gradual improvement in domestic innovative drug clinical operations by 2026 [3]. - The anticipated earnings per share (EPS) for 2026, 2027, and 2028 are 1.38 yuan, 1.83 yuan, and 2.37 yuan, respectively, with corresponding price-to-earnings (PE) ratios of 39, 29, and 23 times [4][10].